Pharmacology of JNJ-42314415, a Centrally Active Phosphodiesterase 10A (PDE10A) Inhibitor: A Comparison of PDE10A Inhibitors with D2 Receptor Blockers as Potential Antipsychotic Drugs-Reference-Cited by-同舟云学术

Pharmacology of JNJ-42314415, a Centrally Active Phosphodiesterase 10A (PDE10A) Inhibitor: A Comparison of PDE10A Inhibitors with D2 Receptor Blockers as Potential Antipsychotic Drugs

Published:2014-01-13 Issue:1 Volume:349 Page:138-154
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Megens Anton A. H. P.^ORCID,Hendrickx Herman M. R.,Hens Koen A.,Fonteyn Ineke,Langlois Xavier,Lenaerts Ilse,Somers Marijke V. F.,de Boer Peter,Vanhoof Greet

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference39 articles.

1. Immunohistochemical Localization of Phosphodiesterase 10A in Multiple Mammalian Species

2. Results of a phase 2a proof-of-concept trial with a PDE10A inhibitor in the treatment of acute exacerbation of schizophrenia;DeMartinis;Schizophr Res,2012

3. Dopamine Synthesis Capacity in Patients With Treatment-Resistant Schizophrenia

4. Neuroleptic-induced hyperprolactinemia

5. Influence of Phasic and Tonic Dopamine Release on Receptor Activation

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhalable cardiac targeting peptide modified nanomedicine prevents pressure overload heart failure in male mice;Nature Communications;2024-07-18

2. Inhibition of phosphodiesterase 10A by MP-10 rescues behavioral deficits and normalizes microglial morphology and synaptic pruning in a mouse model of FOXP1 syndrome;2024-03-05

3. Tolerance to paradoxical increase in motor activity caused by inhibition of phosphodiesterase 10a in a model of hypodopaminergy;The Scientific Notes of the Pavlov University;2023-12-08

4. Inhibition of PDE10A in a New Rat Model of Severe Dopamine Depletion Suggests New Approach to Non-Dopamine Parkinson’s Disease Therapy;Biomolecules;2022-12-21

5. Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules;Frontiers in Pharmacology;2022-11-24